A new report reveals that only 2.3% of eligible individuals with obesity are prescribed anti-obesity medication, despite record-high sales. Blockbuster drugs like Wegovy and Zepbound are gaining traction, with Novo Nordisk acquiring Cardior in a $1B deal. Amgen is entering the weight loss drug market with MariTide, aiming to capitalize on the booming industry projected to reach $100B by the end of the decade. Amazon and DTC telemedicine platforms are benefiting from the demand for weight loss drugs. Amgen is suing Colorado over prescription drug affordability, while Novo Nordisk is seeking German insurance coverage for Wegovy.
Amgen accused a Colorado board of violating the U.S. Constitution with its first-in-the-nation plan to cap the cost of a pricey prescription medicine. https://t.co/77SOmF28vk
Pharmalittle: We’re reading about Amgen suing Colorado over drug cost caps, abortion pills, and more.. https://t.co/BORp6TOKZn #pharma #obesity #weightloss #insulin #chickens #antibiotics #Colorado #China #abortion $AMGN $PFE $AZN $NVO $LLY
$BEAM base editing candidate for liver+lung alpha-1-antitrypsin disease clears CTA: https://t.co/VyxcHQ0YMW Follows on heels of $WVE #RNAediting approach, $KRRO a bit behind.
“Amazon’s online pharmacy business is benefiting from the frenzied demand for anti-obesity drugs among Americans” https://t.co/scqO0zcGhC
Amgen filed a lawsuit accusing a Colorado state board of violating the Constitution over a plan to pursue a cap on the cost of a pricey prescription medicine. https://t.co/KxeNuOsL54
Enbrel drugmaker sues over Colorado’s potential price cap, says prescription drug board is unconstitutional https://t.co/MoyPoU1ER5
Ever since I started helping people reverse chronic diseases with food, I’m proud to say that I’ve never had to add a new medication for diabetes or obesity, and rarely added a blood pressure medication for a short time. Almost always, people were able to come off medications.
Amgen sues Colorado over its prescription drug affordability board.. the drug company claims its unconstitutional.. read why here.. https://t.co/WSuIcBPCLO #pharma #raredisease #affordable #medicines #orphandrug #Enbrel #Colorado $AMGN
Amazon hopes anti-obesity drug demand will boost pharmacy business https://t.co/CfeWYzFXAh
📝Obesity: important to note this is not all about which agent can maximize weight loss. In the end there are going to be different sub-markets. Oral may be more about tolerability. Some of the combos will likely be dispensed based on comorbity. For example obese NASH…
Drug Channels News Roundup, March 2024: - What @CarelonRx/@Kroger means for @CVSHealth - Provider-owned specialty #pharmacies in #Medicare - Payers on shady #AFPs - #340B deception by @ahahospitals & @healthsperien - @EliLillyandCo on GLP1-s https://t.co/faAbq2GMng
Excited to share that UK regulators have cleared the clinical trial application for BEAM-302 as a potential treatment for alpha-1 antitrypsin deficiency! We are on track to initiate the trial in the first half of 2024. https://t.co/TZQdPgt76e
Week’s deals feature AZ-Fusion, Novo Nordisk-Cardior acquisitions. Plus: Intellia ops out of co-developing Factor-IX therapy with Regeneron and GSK returns Sosei’s GPR35 agonist after deprioritization https://t.co/0bT4WGQfsB
Much of the obesity drug hype is driven by media coverage. That’s not to say these drugs haven’t done or are not doing a lot of good. But, we know it’s not tied to health outcomes bc surgery gets a fraction of the coverage despite superior health outcomes for more advanced dz. https://t.co/yCGxn5u1yI
Obesity drugs are reshaping science, business, health care, and society. STAT's new report gathers articles from the #ObesityRevolution series to guide you around this rapidly changing landscape: https://t.co/rjwQuIcEbg #STATReports https://t.co/nkaGfDwLdL
3 prescription drug insurance companies/PBMs control nearly 80% of all prescriptions in US. Pittsburgh-area independent drugstore owners say that 1 of them, Express Scripts/Cigna,has been cutting reimbursement so much that drugstores are being forced out of business. Story below https://t.co/DsWhfmpEJa
A brand new drug from $BHVN promises to promote muscle gain in patients taking GLP-1 obesity drugs CEO Vlad Coric breaks down the treatment's latest clinical trial results and how soon it could impact patients and the weight loss space: https://t.co/v19ENpgVlQ
$AMGN Daily pulled back and started to base above the 200ma. Gap up caught my eye and today back over 10/21ma's (position) https://t.co/S0zAzVlbQ3
$AMGN back over 10/21ma daily (new position today)
$LLY wound up with a 150 pt consol range since Feb. Hedge looking at taking a few more #shots
The scales of #weightloss drugs accessibility don’t exactly tip in favor of people of color who are at greater risk for developing issues with #weight management. Hit the 🔗 to discover why this is happening @CultureBanx. #ozempic https://t.co/N40JJRlWaU https://t.co/ONoqOZ515C
$AMGN worth a look as it reclaims the 20 https://t.co/sjc6LxrKNq
Novo ready to seek German insurance coverage of Wegovy for heart use https://t.co/tWWsQCUts2 https://t.co/2o3VGZllPl
This is by no means scientific and it’s a small number, but it should make you wonder and ask questions about conventional medical advice for T2D. 78% got worse following conventional advice, while 92% got better or went into remission on a low carb diet. Make your own judgement. https://t.co/lXbZfEgNBH
Novo to acquire heart failure drug in $1B deal for Cardior https://t.co/IDdsaJmn9e $NVO by @NedPagliarulo
Novo to acquire heart failure drug in deal for Cardior https://t.co/kwq7ejyDKN by @NedPagliarulo $NVO
$AMGN Amgen is aiming to enter the weight loss drug market with MariTide, an injectable that may require less frequent dosing. Initial trials show promise in maintaining weight loss, setting it apart in a market poised to be worth $100B by decade's end
Low carb diets very frequently result in people coming off multiple medications, and yet they are often demonized by the main stream press and the pharma doctors! Why could that be?? https://t.co/P3o7SFVPeo
Wow, microRNAs back en vogue --> $RGLS Cardior aims at heart, delivery likely supported by $NVO know-how. $PRQR $LLY https://t.co/F4prLP2jq4
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a Novo Nordisk deal, a Regeneron setback & more news.. https://t.co/8vaZPk6fP1 #pharma #Covid #Alzheimer #abortion #AIDS #insulin #weightloss #obesity #Wegovy #SCOTUS $NVO $LLY $BNTX $PFE $REGN $EISAIY
$AMGN (+0.9% pre) Amgen wants in on the booming weight loss drug market — and it’s taking a different approach - CNBC https://t.co/b6ksc3xovA
Weight-loss drugs will not be the only blockbusters against this silent killer https://t.co/n8QLBU4WJi | opinion
Reverse Diabetes Naturally: Inspiring Stories and Effective Strategies #ReverseDiabetes #LowCarbDiet #InsulinDependence #NaturalHealth #BloodPressureControl #HealthyLifestyle #InspiringStories #HealthStrategies #HypertensionTreatment #WellnessJourney https://t.co/qoCCASYIgp
🇺🇸 Weight loss drugs like Ozempic are giving DTC telemedicine platforms a boost https://t.co/rmIs46KRsg
Small acquisition by $NVO upto 1B euros for Cardior https://t.co/LvvMx1l3X9
The weight loss drug race has Amgen coming for Novo Nordisk and Eli Lilly https://t.co/0neRbjjgnx
Wow $NVO $LLY $AMGN I don’t intend to ever stop taking this medicine,” said Kimberly DelRosso of Pembroke, Massachusetts, who takes Wegovy. She has never forgotten to take her weekly injection. By contrast, she says, she often neglected to take the blood pressure pills she was… https://t.co/TqhXm3AMjM
$AMGN coming after #TripleShot $LLY. Should be an active week again $TSLA - short week with 1 more OE before production. We’ll see what Goldman serves up early tomorrow $DIS - into an intermediate target zone as bulls spring up left and right. Proxy fight is noise Hagn
Most people, study after study shows, don’t take the medicines prescribed for them. But that resistance may be overcome by the blockbuster obesity drugs Wegovy and Zepbound. (Via @nytimes) https://t.co/eIld2j0MRl
Obesity drug sales reach an all-time high but still represent only a fraction of what's possible (<3% of eligible people are taking them). https://t.co/vt39ubsjaX https://t.co/LdddZpfkfT
Patients don’t take the medicines prescribed to them, leading to countless deaths, studies show. So what makes obesity drugs different? https://t.co/VMxa4vujw9
🚨NEW REPORT: Even among the insured, only 2.3% of qualifying people with obesity are prescribed anti-obesity medication. https://t.co/GcQc29HHzE